Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants prior to extubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
a) Cerebral palsy or gross motor disability · preterm infants prior to extubation
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
1 finding from 1 review
b) Developmental delay at 18 to 24 months · preterm infants prior to extubation
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Failed extubation · preterm infants prior to extubation
Methylxanthine probably leads to lower failed extubation compared with placebo or control (moderate certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants prior to extubation
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
1 finding from 1 review
a) Cerebral palsy or gross motor disability · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
1 finding from 1 review
b) Developmental delay at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Any apneic episodes · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower any apneic episodes compared with placebo or control (moderate certainty).
1 finding from 1 review
Failed apnea reduction · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower failed apnea reduction compared with placebo or control (moderate certainty).
1 finding from 1 review
Positive‐pressure ventilation after institution of treatment · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine may leads to lower positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (high certainty).
1 finding from 1 review
Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line
CHG‐IPA showed no clear difference in proven catheter‐related bloodstream infection (CRBSI) expressed by… compared with PI (low certainty).
1 finding from 1 review
Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line
CHG‐IPA showed no clear difference in premature central line removal, defined as number of central venous… compared with CHG‐A (moderate certainty).
1 finding from 1 review
Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) · neonates that require central line
CHG‐IPA showed no clear difference in chemical burns or contact dermatitis, measured using a scoring… compared with CHG‐A (moderate certainty).
1 finding from 1 review
Mortality before hospital discharge · neonates that require central line
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Central line‐associated bloodstream infection (CLABSI) expressed using absolute rates of infants · neonates that require central line
It is very uncertain whether CHG‐IPA changes central line‐associated bloodstream infection (CLABSI) expressed… compared with PI (very low certainty).
1 finding from 1 review
Exit‐site infection · neonates that require central line
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) · neonates that require central line
It is very uncertain whether CHG‐IPA changes chemical burns or contact dermatitis, measured using a scoring… compared with PI (very low certainty).
1 finding from 1 review